Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Guinea pigs were infected with Aspergillus fumigatus at two challenge doses and treated for 7 days with a placebo, intraperitoneal caspofungin (1 mg/kg daily), oral voriconazole (1 mg/kg twice a day), or a combination of the caspofungin and voriconazole treatments. The combination therapy statistically significantly prolonged survival over that with the control at both challenge doses and achieved a statistically significant reduction in kidney burdens as measured by quantitative PCR. The same was true for animals given caspofungin alone at both levels of challenge and for animals treated with voriconazole alone at the lower challenge dose. However, the effects of combination therapy on prolongation of survival were greater than those of either monotherapy at both challenge doses, and the reduction in kidney burdens with combination therapy was significantly greater than that with caspofungin alone in the animals given the lower challenge dose. No synergistic interactive effects were seen for the two agents in checkerboard titration experiments in vitro. We conclude that therapy of experimental aspergillosis with caspofungin and voriconazole combined offers slight additional improvements in efficacy rather than effects of a clearly synergistic nature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85 · cited 1×
“The clinical availability of two new antifungal agents, caspofungin and voriconazole, with different modes of action (10, 11) has heightened interest in combinations of antifungal agents as a means of improving outcomes in life-threatening fungal infections, particularly aspergillosis (4, 13, 14, 23).”
Background
Cited by
Singh, N., Limaye, A. P., Forrest, G., Safdar, N., Mu??oz, P., Pursell, K., Houston, S., Rosso, F., Montoya, J. G., Patton, P., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000202421.94822.f7 · Cited by 336
Meletiadis, J., Pournaras, S., Roilides, E., & Walsh, T. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-09 · Cited by 325
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
“For example, a number of fixed-dose studies have suggested potential benefits of combination therapy (Kirkpatrick et al. 2002; Petraitis et al. 2003, 2009; Chandrasekar et al. 2004; MacCallum et al. 2005; van de Sande et al. 2009).”
BackgroundDesoubeaux, G., & Cray, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00841 · Cited by 55
“, 2016), especially for addressing clinical efficacy and pharmacodynamics/pharmacokinetics of echinocandin or azoles (Van Cutsem et al., 1989, 1990; Cutsem et al., 1993; Arrese et al., 1994; Overdijk et al., 1996, 1999; Reichard et al., 1997; Odds et al., 1998, 2000; Kirkpatrick et al., 2000b, 2002, 2006; Loeffler et…”
BackgroundAerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis
Alvarez, C. A., Wiederhold, N. P., McConville, J. T., Peters, J. I., Najvar, L. K., Graybill, J. R., Coalson, J. J., Talbert, R. L., Burgess, D. S., Bocanegra, R., et al. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.01.014 · Cited by 43
Metadata
- Authors
- MacCallum, D. M., Whyte, J. A., & Odds, F. C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2005-09
- Volume
- 49
- Issue
- 9
- Pages
- 3697-3701
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2154515975
- Cited by
- 73
- References
- 1
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis. https://app.cochat.ai/papers/10.1128/aac.49.9.3697-3701.2005
- The paper
- MacCallum, D. M., Whyte, J. A., & Odds, F. C. (2005). Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.49.9.3697-3701.2005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.